News: HXL Hexima Announces Results Of Phase II Study Of Pezadeftide For Treatment Of Onychomycosis

July 11 (Reuters) - Hexima Ltd (HXL) :

• HEXIMA LTD - RESULTS OF ITS PHASE II CLINICAL STUDY OF PEZADEFTIDE (HXP124) FOR TREATMENT OF ONYCHOMYCOSIS
• HEXIMA LTD - PEZADEFTIDE WAS WELL-TOLERATED AND SAFE
• HEXIMA LTD - HAS INITIATED A PROCESS OF SEEKING EXPRESSIONS OF INTEREST IN PURCHASE OR LONGER TERM LEASE OF FACILITY
• HEXIMA - DOES NOT BELIEVE DATA SUPPORT CO'S GOAL OF DEVELOPING SAFE, MORE EFFECTIVE, CONVENIENT TOPICAL THERAPY WITH SHORTER COURSE OF TREATMENT
• HEXIMA LTD - INTENDS TO WIND DOWN ITS DEVELOPMENT PROGRAM OF PEZADEFTIDE FOR TREATMENT OF ONYCHOMYCOSIS IN AN ORDERLY FASHION
• HEXIMA - INITIATED PROCESS OF EXPLORING STRATEGIC OPTIONS FOR CO SEEKING TO SECURE VALUE FOR CO'S INTELLECTUAL PROPERTY AND RESIDUAL CASH RESOURCES
• HEXIMA LTD - DISCUSSIONS ARE VERY PRELIMINARY AND CONTEMPLATED TRANSACTION OR TRANSACTIONS MAY OR MAY NOT OCCUR
• HEXIMA LTD - INITIATED ORDERLY PROCESS OF WINDING UP VARIOUS MANUFACTURING AND NON- CLINICAL DEVELOPMENT ACTIVITES IN A COST EFFICIENT MANNER
• HEXIMA LTD - EXPENSES ASSOCIATED WITH NON-ESSENTIAL EMPLOYEES AND CONTRACTORS ARE BEING MANAGED IN A COST EFFECTIVE AND ORDERLY MANNER